Hepatoprotective Effects of Aureobasidium pullulans Derived β-1,3–1,6 Glucans in a Murine Model of Non-alcoholic Steatohepatitis

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are highly prevalent conditions characterized by inflammation and fibrosis of the liver, which can progress to cirrhosis and hepatocellular carcinoma if left untreated. Beta-glucan-based biological response modifiers are a potential strategy in lieu of their beneficial metabolic effects. Aureobasidium pullulans strains AFO-202 and N-163 beta-glucans were evaluated in a murine NASH model. Treatment with AP-derived β-glucans significantly reduced liver steatosis, hepatocellular ballooning, inflammatory infiltration, and fibrosis scores compared to controls. Serum levels of ALT and AST were significantly reduced. The study provides the first direct evidence of NASH protection by Aureobasidium pullulans-derived β-1,3–1,6 glucans in an animal model.